Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns
Agency updates guidance after increase in reports of condition to its yellow card schemePatients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said.About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to lose weight, according to recent research. Continue reading...
Agency updates guidance after increase in reports of condition to its yellow card scheme
Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said.
About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to lose weight, according to recent research. Continue reading...
What's Your Reaction?
